Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I, Open-label, Dose-escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of GSK3368715 in Participants With Solid Tumors and DLBCL

Trial Profile

A Phase I, Open-label, Dose-escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of GSK3368715 in Participants With Solid Tumors and DLBCL

Recruiting
Phase of Trial: Phase I

Latest Information Update: 18 Dec 2018

At a glance

  • Drugs GSK-3368715 (Primary)
  • Indications Adenocarcinoma; Bladder cancer; Diffuse large B cell lymphoma; Non-Hodgkin's lymphoma; Non-small cell lung cancer; Pancreatic cancer; Solid tumours; Urogenital cancer
  • Focus Adverse reactions; First in man; Therapeutic Use
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 18 Dec 2018 According to an Epizyme media release, following GSKs (GlaxoSmithKlines) initiation of patient dosing in this trial (GSK336871 is discovered by Epizyme and licensed to GSK), the company has earned an $8 million milestone payment from(GSK).
    • 15 Nov 2018 Status changed from not yet recruiting to recruiting.
    • 20 Sep 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top